Skip to main content
Figure 5 | Journal of Hematology & Oncology

Figure 5

From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

Figure 5

Efficacy of ABT-869 in combination with carboplatin-paclitaxel in a NSCLC xenograft. ABT-869 was administered orally at the indicated dose for 3 weeks and carboplatin-paclitaxel was administered weekly (IP and IV respectively) beginning 3 weeks after inoculation of H1299 cells into the flank of SCID/beige mice. Percent inhibition of tumor size relative to vehicle treated control was calculated at the end of the study is indicated in parentheses in the legend.

Back to article page